H&T Presspart, the market leader in respiratory drug delivery components and devices, has been granted a European patent for its latest product, the eMDI connected metered-dose inhaler.
 
The patent granted focuses on an innovative design to allow the eMDI to validate if a patient has completed a successful actuation of the eMDI inhaler. This is the first granted patent out of a number of running patent applications for H&T Presspart’s eMDI, which further strengthens H&T Presspart’s IP position and demonstrates the strong commitment to the connected medical device market.
H&T Presspart’s eMDI is the first market-ready, fully embedded, connected metered-dose inhaler designed to wirelessly transmit data to the BreatheSmart® respiratory health platform from Cohero Health.
 
The eMDI powered by Cohero® is designed to track, remind and record the patient’s medication use using their smartphone and further enabling collaboration with their physician, caregivers and other stakeholders. The eMDI along with the BreatheSmart® platform enables pharmaceutical manufacturers to bring the best possible care to those with asthma and COPD.

H&T Presspart’s eMDI connected device